Remove 2025 Remove Drug Development Remove HIPAA
article thumbnail

Merative formerly IBM Watson Health poised to launch raft of new products in 2025

Lloyd Price

Exec Summary: Merative, formerly known as IBM Watson Health, is gearing up to introduce a range of new products in 2025. Clinical Development: Clinical Trial Matching: Matches patients to appropriate clinical trials. Real-World Evidence: Leverages real-world data to inform clinical decision-making and drug development.

article thumbnail

HealthTech M&A valuation multiples: 10 Key Variables in 2025

Lloyd Price

Factors to Consider When Assessing Management Quality Experience: The management team's experience in the healthcare industry, particularly in relevant areas such as drug development, medical device manufacturing, or healthcare services, can be a significant advantage.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The 4 Big Gaps in HealthTech: Funding, Trust, Evidence, Valuation

Lloyd Price

Risk Aversion: Investors may be hesitant to invest in early-stage healthtech companies due to the inherent risks and uncertainties associated with medical device and drug development. Regulatory Compliance: Adhering to complex regulatory standards, such as HIPAA and GDPR, can be burdensome and costly.

article thumbnail

Healthcare Interoperability and Cloud Services – 2025 Health IT Predictions

Healthcare IT Today

As we wrap up another year and get ready for 2025 to begin, it is once again time for everyone’s favorite annual tradition of Health IT Predictions! Check out the community’s predictions down below and be sure to follow along as we share more 2025 Health IT Predictions !